Clinical studies with anti–CTLA-4 antibodies in non-melanoma indications
L Calabrò, R Danielli, L Sigalotti, M Maio - Seminars in oncology, 2010 - Elsevier
Available medical treatments have limited impact on the survival of patients with advanced
cancer; therefore, new therapeutic strategies able to generate more effective host's immune
responses against neoplastic cells are being actively pursued. Among these, a recent
approach involves targeting of cytotoxic T-lymphocyte antigen-4 (CTLA-4), a key immune
checkpoint molecule, by monoclonal antibodies (mAbs). Ipilimumab and tremelimumab
represent the prototypes of this new class of immunomodulating mAb and have been …
cancer; therefore, new therapeutic strategies able to generate more effective host's immune
responses against neoplastic cells are being actively pursued. Among these, a recent
approach involves targeting of cytotoxic T-lymphocyte antigen-4 (CTLA-4), a key immune
checkpoint molecule, by monoclonal antibodies (mAbs). Ipilimumab and tremelimumab
represent the prototypes of this new class of immunomodulating mAb and have been …